Free tool
FAERS Monitor: Valstar Preservative Free
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020892 or its brand name (Valstar Preservative Free, Valrubicin). Reports on generic versions are filed under their own applications.
Reports
178
Serious
30
17% of reports
Hospitalization
8
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- underdose26
- bladder instillation procedure24
- accidental exposure to product23
- urge incontinence20
- bladder spasm13
- urinary incontinence11
- pain9
- dysuria8
- burning sensation7
- drug ineffective7
- arthralgia6
- fatigue6
- pollakiuria6
- rash6
- drug intolerance5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 79 |
| 2014 | 26 |
| 2015 | 15 |
| 2016 | 5 |
| 2017 | 10 |
| 2018 | 18 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,981 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bladder instillation procedureSignal | 24 | 1419369.5 | 337966.7 | 2,512,328 |
| urge incontinenceSignal | 20 | 2783.1 | 1831.6 | 51,661 |
| bladder spasmSignal | 13 | 826.2 | 488.6 | 9,838 |
| urinary incontinenceSignal | 11 | 43.9 | 24.8 | 420 |
| underdoseSignal | 26 | 42.1 | 29.5 | 1,006 |
| accidental exposure to productSignal | 23 | 26.4 | 18.0 | 539 |
| dysuriaSignal | 8 | 25.7 | 13.0 | 166 |
| pollakiuriaSignal | 6 | 17.0 | 7.7 | 75 |
| burning sensationSignal | 7 | 11.8 | 5.7 | 59 |
| drug intoleranceSignal | 5 | 6.1 | 2.6 | 17 |
| pain | 9 | 1.7 | 0.9 | 2 |
| arthralgia | 6 | 1.7 | 0.8 | 1 |
| rash | 6 | 1.6 | 0.7 | 1 |
| fatigue | 6 | 0.9 | 0.4 | 0 |
| drug ineffective | 7 | 0.6 | 0.3 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.